PharmaLex Denmark A/S: Financial statements 2013
CVR: 18652439
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
PharmaLex Denmark A/S (CVR 18652439) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 12,677,713 and a net result of DKK 2,468,065 compared with DKK 2,321,466 the year before. That is an increase of 28.6% compared with the year before. Equity in the 2013 report amounted to DKK 6,934,155. The solvency ratio was 49.2%.
- Gross Profit
- DKK 12,677,713
- Profit/Loss
- DKK 2,468,065
- Equity
- DKK 6,934,155
- Total Assets
- DKK 14,086,568
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | 12.7 mio. | 2.5 mio. | 6.9 mio. | - |
| 2012 | - | 9.9 mio. | 2.3 mio. | 7.2 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
PharmaLex Denmark A/S has published its annual report for 2012. Gross profit came to DKK 9,854,675, and the net result was DKK 2,321,466.
About PharmaLex Denmark A/S
PharmaLex Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 1995. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named JACOBSEN PHARMA CONSULTANCY A/S and SLP NR. 11.026 A/S. The management consists of Åsa Pihlblad. The board consists of Christopher Gauglitz (chair), Carlos Antonio Santaflorentina Juanino and Åsa Pihlblad. The company is owned by Pharmalex Nordic ApS. The company has 15 employees (2026). In 2025, the company reported a gross profit of DKK 17,235,093 and a net result of DKK -1,712,095 compared with DKK 1,745,746 the year before. Equity in the 2025 report amounted to DKK 2,761,242.